title: Regulation of the ventral tegmental area by the bed nucleus of the stria terminalis is required for expression of cocaine preference.
abstract: Lateral hypothalamus (LH) orexin neurons are essential for the expression of a cocaine place preference. However, the afferents that regulate the activity of these orexin neurons during reward behaviors are not completely understood. Using tract tracing combined with Fos staining, we examined LH afferents for Fos induction during cocaine preference in rats. We found that the ventral bed nucleus of the stria terminalis (vBNST) was a major input to the LH orexin cell field that was significantly Fos-activated during cocaine conditioned place preference (CPP). Inactivation of the vBNST with baclofen plus muscimol blocked expression of cocaine CPP. Surprisingly, such inactivation of the vBNST also increased Fos induction in LH orexin neurons; as activity in these cells is normally associated with increased preference, this result indicates that a vBNST-orexin connection is unlikely to be responsible for CPP that is dependent on vBNST activity. Because previous studies have revealed that vBNST regulates dopamine cells in the ventral tegmental area (VTA), which is known to be involved in CPP and other reward functions, we tested whether vBNST afferents to the VTA are necessary for cocaine CPP. We found that disconnection of the vBNST and VTA (using local microinjections of baclofen plus muscimol unilaterally into the vBNST and contralateral VTA) significantly attenuated expression of cocaine preference. However, blocking ionotropic glutamatergic afferents to the VTA from the vBNST did not significantly reduce cocaine preference. These results indicate that a non-glutamatergic vBNST-VTA projection is involved in expression of cocaine preference.
authors.affiliation: Department of Neurosciences, Medical University of South Carolina, 171 Ashley Avenue, BSB 403, Charleston, SC 29425, USA.
authors.forename: Gregory C
authors.initials: GC
authors.lastname: Sartor
authors.forename: Gary
authors.initials: G
authors.lastname: Aston-Jones
mesh_terms: D000818:Animals; D001418:Baclofen / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D059290:Dopaminergic Neurons / Q000502:physiology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D058786:GABA-B Receptor Agonists / Q000494:pharmacology; D008297:Male; D009118:Muscimol / Q000494:pharmacology; D056325:Neuronal Tract-Tracers / Q000032:analysis; D009475:Neurons, Afferent / Q000502:physiology; D016760:Proto-Oncogene Proteins c-fos / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012686:Septal Nuclei / Q000502:physiology*; D017557:Ventral Tegmental Area / Q000502:physiology*
chemical_list: D018765:Dopamine Uptake Inhibitors; D018691:Excitatory Amino Acid Antagonists; D058786:GABA-B Receptor Agonists; D056325:Neuronal Tract-Tracers; D016760:Proto-Oncogene Proteins c-fos; D009118:Muscimol; D001418:Baclofen; D003042:Cocaine